Results 151 to 160 of about 772,552 (212)

Pseudohomozygous and Pseudoheterozygous Type II Hyperlipoproteinemia

Archives of Pediatrics & Adolescent Medicine, 1976
A 4-year-old boy had typical features of homozygous type II hyperlipoproteinemia with planar xanthomas, a plasma cholesterol level greater than 600 mg/dl, and an estimated beta-lipoprotein cholesterol concentration greater than 500 mg/dl. Both he and his sister, who had the biochemical features of the heterozygous state, responded unusually well to a ...
Maurice A. Mishkel
openaire   +3 more sources

Neomycin and plasma lipoproteins in type II hyperlipoproteinemia

Clinical Pharmacology and Therapeutics, 1984
Neomycin, a nonabsorbable aminoglycoside antibiotic, has been shown to exert a hypocholesterolemic effect in man. In a 9-mo, double-blind, randomized, crossover, placebo-controlled clinical trial, the effect of neomycin, 2 gm/day, on plasma lipoproteins, as well as its safety, was described in 20 subjects with type II hyperlipoproteinemia. A 15% (50 mg%
Jeffrey M Hoeg, Ernst J Schaefer, Carol A Romano, Ernestina Bou, Anita M Pikus, Loren A Zech, Kent R Bailey, Richard E Gregg, Peter W F Wilson, Dennis L Sprecher, Alison M Grimes, Nancy G Sebring, Elaine J Ayres, Claus E Jahn, H B Brewer   +14 more
openaire   +3 more sources

Controlled trial of acifran in type II hyperlipoproteinemia

Clinical Pharmacology and Therapeutics, 1985
The hypolipidemic effects of acifran were evaluated in a randomized, double-blind, placebo-controlled study of 30 patients with type IIa hyperlipoproteinemia. Plasma lipid and lipoprotein values were determined at baseline (mean of three values), again after a 2-week single-blind period of acifran dosing, and at 2-week intervals during a 10-week period
D B, Hunninghake, K D, Edwards, G S, Sopko, R L, Tosiello   +3 more
openaire   +3 more sources

Homozygous Type II Hyperlipoproteinemia Treatment

JAMA, 1974
Dietary treatment was minimally effective in two children with homozygous type II hyperlipoproteinemia who had no evidence of atherosclerosis. Neither patient could tolerate cholestyramine resin in therapeutic doses. A partial ileal bypass operation was performed on each child, aged 10 and 8 years old.
John F. Balfour
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Hypertrophy of liver peroxisomes in type II and type IV hyperlipoproteinemia

Atherosclerosis, 1986
A morphometric study on liver biopsies from patients with primary hyperlipoproteinemia (IIa n = 4, IIb n = 7, IV n = 7) and in controls (n = 7) was performed by light and electron microscopy. We found hypertrophy of peroxisomes in all subjects with hyperlipoproteinemia.
P Drouin, G Debry
exaly   +3 more sources

Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia

Atherosclerosis, 1995
Yasuhiko Homma, Hideki Ozawa, Hiroshi Yamaguchi   +2 more
exaly   +2 more sources

Mevinolin and Neomycin in the Treatment of Type II Hyperlipoproteinemia

, 1987
The reduction of elevated low-density lipoprotein (LDL) cholesterol concentrations in patients with type II hyperlipoproteinemia leads to improved cardiovascular morbidity and mortality. Two agents that may be of value in treating hypercholesterolemia are mevinolin and neomycin.
Jeffrey M. Hoeg, Martha B. Maher, Kent R. Bailey, Silvia S. Fojo, H. Bryan Brewer   +4 more
openaire   +2 more sources

Treatment of Familial Hyperlipoproteinaemia Type II

Clinical Science, 1971
N. Myant
openaire   +3 more sources

Pseudohomozygous Type II Hyperlipoproteinemia

Dermatologica, 2009
Nodular xanthomas on both elbows and a streak-like xanthoma on the intergluteal area developed in a 4-year-old girl with type IIa hyperlipoproteinemia. She had no disease associated with secondary hypercholesterolemia and no family history of hypercholesterolemia. Her xanthomas regressed under fat restriction diet and cholestyramine therapy.
M, Fujita, S, Okamoto, K, Shirai, Y, Saito, S, Yoshida   +4 more
openaire   +2 more sources

Pseudohomozygous type II hyperlipoproteinemia

The Journal of Pediatrics, 1974
Familial hypercholesterolemia (a form of familial type II hyperlipoproteinemia) is transmitted as a dominant trait with homozygotes presenting in childhood with marked elevation of LDL and planar xanthormas. We studied two patients who presented as children with marked elevation of LDL and planar xanthomas but who, after family studies and clinical ...
J, Morganroth, R I, Levy, A E, McMahon, A M, Gotto   +3 more
openaire   +2 more sources